News & Updates

No benefit to SGLT2 inhibitor therapy in hospitalized COVID-19 patients
No benefit to SGLT2 inhibitor therapy in hospitalized COVID-19 patients
15 Sep 2024
Fewer CV events after COVID-19 vaccine-related myocarditis
Fewer CV events after COVID-19 vaccine-related myocarditis
13 Sep 2024 byElvira Manzano

In a nationwide French cohort study, myocarditis attributed to COVID-19 mRNA vaccination causes fewer cardiovascular (CV) events at 18 months of follow-up than that attributed to SARS-CoV-2 infection or myocarditis of conventional aetiologies.

Fewer CV events after COVID-19 vaccine-related myocarditis
13 Sep 2024